stockrowProtagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.
- Revenue
- +3,749.2%
- EPS
- +549.1%
- Free cash flow
- +839.7%
Quarter to June 2026, against a year earlier
Follow PTGX
Alert me
Protagonist Therapeutics, Inc. (PTGX) EBITDA
Protagonist Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$162.5M, compared with $246.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was $56.4M. Over the past ten years it has ranged from −$162.5M (fiscal 2025) to $246.9M (fiscal 2024) — the current reading is the lowest in ten years. Protagonist Therapeutics, Inc. ranks 31st of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$162.5M | — |
| FY2024 | $246.9M | — |
| FY2023 | −$94.9M | — |
| FY2022 | −$128.6M | — |
| FY2021 | −$121.2M | — |
| FY2020 | −$61.8M | — |
| FY2019 | −$78.6M | — |
| FY2018 | −$41.5M | — |
| FY2017 | −$36.8M | — |
| FY2016 | −$32.2M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $157.7M | — |
| Mar 2026 | −$3.8M | — |
| Dec 2025 | −$51.0M | — |
| Sep 2025 | −$46.5M | — |
| 40 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $234.3M |
| CAI Caris Life Sciences,�Inc. compare | $180.0M |
| TGTX TG Therapeutics, Inc. compare | $136.0M |
| PTGX Protagonist Therapeutics, Inc. | $56.4M |
| TWST Twist Bioscience Corporation compare | −$119.6M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$145.8M |
| IBRX ImmunityBio, Inc. compare | −$235.2M |
| SYRE Spyre Therapeutics, Inc. compare | −$250.2M |
| CYTK Cytokinetics, Incorporated compare | −$694.7M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on PTGX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement